{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:28:51Z","timestamp":1786634931611,"version":"build-2736575974"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment resistant depression (TRD) is a burdensome condition with a severe impact on patients\u2019 everyday lives. Therapeutics have improved in the last decade, however, outcomes remain poor. Real-world characterization has become increasingly important to accurately depict the clinical setting. ResisToday was an observational, prospective, multicenter study that aimed to increase available real-world evidence by evaluating clinical and socio-demographics, treatment patterns and clinical and patient-reported outcomes (PROs) of patients with TRD in Portugal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with a clinical diagnosis of TRD and moderate to severe depression (Montgomery-\u00c5sberg Depression Rating Scale [MADRS] score \u226522), who were initiating a new treatment for TRD could enroll in ResisToday. Clinical outcomes were evaluated using the MADRS and the Clinical Global Impression-Severity scale (CGI-S). PROs were reported using the Patient Health Questionnaire-9 (PHQ-9) and EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Outcomes were assessed at baseline, Week 4 (primary endpoint) and Week 20.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 153 patients, 123 (80.4%) were female and the mean age was 53.9 years. The mean age of onset of clinical depression symptoms was 38.0 years, and the mean time since diagnosis of major depressive disorder (MDD) was 11.8 years. TRD treatments initiated at baseline were varied; the most common treatments initiated or ongoing at baseline were mirtazapine (43.1%), venlafaxine (42.5%), quetiapine (25.5%), and trazodone (20.9%). Most patients\u2019 antidepressant treatment was augmented with an antipsychotic (36.6%), combined with additional antidepressants (22.2%), or combined with another augmentation strategy (19.0%). Improvements in MADRS were observed from baseline to Week 4 and Week 20 (both p&amp;lt;0.001). Clinical response and remission, assessed by MADRS, were achieved by 14.9% and 3.1% of patients, respectively, at Week 4, and 40.5% and 25.3% at Week 20. Improvements were observed across CGI-S, PHQ-9, and EQ-5D-5L measures through Week 20 (all p&amp;lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Outcomes for patients with TRD in real-world clinical practice remain poor, with most patients not responding after 20 weeks of treatment. Treatment heterogeneity highlights a lack of clinical consensus, and the need for novel therapeutics and improved treatment protocols for TRD in real-world clinical practice in Portugal.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1749006","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:36:00Z","timestamp":1786631760000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient characteristics, treatment patterns and clinical response in patients with treatment resistant depression starting a new treatment in the clinical setting: a multicenter, observational study in Portugal"],"prefix":"10.3389","volume":"17","author":[{"given":"Ricardo","family":"Moreira","sequence":"first","affiliation":[{"name":"Unidade Local de Sa\u00fade de S\u00e3o Jo\u00e3o","place":["Porto, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Frade","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade do Oeste","place":["Caldas da Rainha, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Campe\u00e3o","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade da P\u00f3voa de Varzim\/Vila do Conde","place":["Vila do Conde, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Gomes","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Santo Ant\u00f3nio","place":["Porto, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Lopes","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Santo Ant\u00f3nio","place":["Porto, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Lapa","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Gaia\/Espinho","place":["Vila Nova de Gaia, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Vian","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Lisboa Ocidental","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade da Regi\u00e3o de Leiria","place":["Leiria, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1via","family":"Polido","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade do Algarve","place":["Faro, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Barata","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade do Arco Ribeirinho","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mota","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Coimbra","place":["Coimbra, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcio","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade do Alto Minho","place":["Viana do Castelo, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaroslava","family":"Martins","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade do Baixo Alentejo","place":["Beja, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Nascimento","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de S\u00e3o Jos\u00e9","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lic\u00ednio","family":"Santos","sequence":"additional","affiliation":[{"name":"Hospital Dr. N\u00e9lio Mendon\u00e7a","place":["Funchal, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Mendes","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade da Guarda","place":["Guarda, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Dur\u00e3es","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade da Arr\u00e1bida","place":["Set\u00fabal, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade do M\u00e9dio Tejo","place":["Abrantes, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulce","family":"Maia","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Tr\u00e1s-os-Montes e Alto Douro","place":["Vila Real, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Cunha","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Viseu D\u00e3o-Laf\u00f5es","place":["Viseu, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara","family":"Cochicho","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Innovative Medicine","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gon\u00e7alo","family":"Amorim","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Innovative Medicine","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Ponte","sequence":"additional","affiliation":[{"name":"Hospital do Divino Esp\u00edrito Santo","place":["Ponta Delgada, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B1","unstructured":"Depressive disorder (depression)\n          \n          \n          \n          2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41392-024-01738-y","article-title":"Major depressive disorder: Hypothesis, mechanism, prevention and treatment","volume":"9","author":"Cui","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.S29716","article-title":"Treatment-resistant depression: Therapeutic trends, challenges, and future directions","volume":"6","author":"Al-Harbi","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2009.60.11.1439","article-title":"What did Star*D teach us? Results from a large-scale, practical, clinical trial for patients with depression","volume":"60","author":"Gaynes","year":"2009","journal-title":"Psychiatr Serv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300059","article-title":"A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013","volume":"65","author":"Mrazek","year":"2014","journal-title":"Psychiatr Serv"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01381-x","article-title":"A delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials","volume":"27","author":"Sforzini","year":"2022","journal-title":"Mol Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2021.05.026","article-title":"Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study","volume":"139","author":"Denee","year":"2021","journal-title":"J Psychiatr Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0140","article-title":"Medicaid spending burden among beneficiaries with treatment-resistant depression","volume":"8","author":"Pilon","year":"2019","journal-title":"J Comp Eff Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12888-019-2222-4","article-title":"The humanistic and economic burden of treatment-resistant depression in Europe: A cross-sectional study","volume":"19","author":"Jaffe","year":"2019","journal-title":"BMC Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jad.2018.06.045","article-title":"The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature","volume":"242","author":"Johnston","year":"2019","journal-title":"J Affect Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11725","article-title":"Direct and indirect cost burden and change of employment status in treatment-resistant depression: A matched-cohort study using a US commercial claims database","volume":"79","author":"Amos","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1588902","article-title":"Editorial: Treatment resistant depression (TRD): Epidemiology, clinic, burden and treatment","volume":"16","author":"Fiorillo","year":"2025","journal-title":"Front Psychiatry"},{"key":"B14","article-title":"Intranasal esketamine (Spravato\u2122) for use in treatment-resistant depression in conjunction with an oral antidepressant","volume":"44","author":"Bahr","year":"2019","journal-title":"P T"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2019-100074","article-title":"Efficacy of repetitive transcranial magnetic stimulation in treatment-resistant depression: The evidence thus far","volume":"32","author":"Somani","year":"2019","journal-title":"Gen Psychiatr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1517\/14656561003614781","article-title":"Pharmacologic approaches to treatment resistant depression: A re-examination for the modern era","volume":"11","author":"Philip","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2023.5","article-title":"Response to electroconvulsive therapy in treatment-resistant depression: Nationwide observational follow-up study","volume":"9","author":"Nygren","year":"2023","journal-title":"BJPsych Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00205-y","article-title":"Treatment-resistant depression: Molecular mechanisms and management","volume":"5","author":"Kajumba","year":"2024","journal-title":"Mol BioMed"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadr.2024.100791","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: Country-specific data for Portugal","volume":"17","author":"Bessa","year":"2024","journal-title":"J Affect Disord Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.03.073","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes","volume":"290","author":"Heerlein","year":"2021","journal-title":"J Affect Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.11.004","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: Healthcare resource utilization","volume":"298","author":"Heerlein","year":"2022","journal-title":"J Affect Disord"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.1372","article-title":"Hsd28 most common treatments in patients with treatment resistant depression based on European cohort study real-world evidence","volume":"25","author":"Heerlein","year":"2022","journal-title":"Value Health"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.11.124","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics","volume":"283","author":"Heerlein","year":"2021","journal-title":"J Affect Disord"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1623659","article-title":"Treatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects","volume":"16","author":"Mora","year":"2025","journal-title":"Front Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.824919","article-title":"Treatment-resistant depression in Portugal: Perspective from psychiatry experts","volume":"13","author":"Bessa","year":"2022","journal-title":"Front Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.898491","article-title":"Treatment-resistant depression and major depression with suicide risk-the cost of illness and burden of disease","volume":"10","author":"Sousa","year":"2022","journal-title":"Front Public Health"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.1388","article-title":"The structure of the Montgomery-\u00c5sberg depression rating scale over the course of treatment for depression","volume":"22","author":"Quilty","year":"2013","journal-title":"Int J Methods Psychiatr Res"},{"key":"B28","first-page":"28","article-title":"The clinical global impressions scale: Applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: Validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-023-02215-w","article-title":"Health-related quality of life in primary care patients: A comparison between EQ-5D-5L utility score and EQ-visual analogue scale","volume":"22","author":"Xu","year":"2024","journal-title":"Health Qual Life Outcomes"},{"key":"B31","doi-asserted-by":"publisher","first-page":"50375","DOI":"10.4088\/jcp.23r14885","article-title":"Predictors and risk factors of treatment-resistant depression: A systematic review","volume":"85","author":"O\u2019Connor","year":"2024","journal-title":"J Clin Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.09.033","article-title":"Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study","volume":"189","author":"Balestri","year":"2016","journal-title":"J Affect Disord"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.S198774","article-title":"Management of treatment-resistant depression: Challenges and strategies","volume":"16","author":"Voineskos","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1221746","article-title":"Treatment-resistant depression in America Latina study: One-year follow-up of treatment resistant depression patients under standard of care reveals insights on quality of life, disability, work impairment, and depressive symptoms","volume":"14","author":"Recco","year":"2023","journal-title":"Front Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12888-018-1920-7","article-title":"Humanistic outcomes in treatment resistant depression: A secondary analysis of the Star*D study","volume":"18","author":"DiBernardo","year":"2018","journal-title":"BMC Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13260","article-title":"Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression","volume":"143","author":"Turkoz","year":"2021","journal-title":"Acta Psychiatr Scand"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15596","article-title":"Perspectives for therapy of treatment-resistant depression","volume":"179","author":"Papp","year":"2022","journal-title":"Br J Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.12.044","article-title":"Comorbidity and healthcare utilization in patients with treatment resistant depression: A large-scale retrospective cohort analysis using electronic health records","volume":"324","author":"Adekkanattu","year":"2023","journal-title":"J Affect Disord"},{"key":"B40","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1186\/s12888-020-02935-z","article-title":"Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study","volume":"20","author":"Huang","year":"2020","journal-title":"BMC Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2174\/011570159X392347250929114024","article-title":"Gender Differences in Suicidal and Self-Harming Responses to Esketamine: A Real-World Retrospective Study","author":"Martiadis","year":"2025","journal-title":"Curr Neuropharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.11.004","article-title":"Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression","volume":"227","author":"Olgiati","year":"2018","journal-title":"J Affect Disord"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13800","article-title":"Treatment response with esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression without evidence of early response: A pooled post hoc analysis of the Transform studies","volume":"82","author":"Turkoz","year":"2021","journal-title":"J Clin Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115165","article-title":"Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray","volume":"323","author":"Turkoz","year":"2023","journal-title":"Psychiatry Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-World Experience of Esketamine Use to Manage Treatment-Resistant Depression: A Multicentric Study on Safety and Effectiveness (Real-Esk Study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J Affect Disord"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115378","article-title":"Predicting Outcome with Intranasal Esketamine Treatment: A Machine-Learning, Three-Month Study in Treatment-Resistant Depression (Esk-Learning)","volume":"327","author":"Pettorruso","year":"2023","journal-title":"Psychiatry Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jad.2008.10.014","article-title":"What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies","volume":"116","author":"Fekadu","year":"2009","journal-title":"J Affect Disord"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.08.046","article-title":"Antidepressant treatment outcomes in patients with and without comorbid physical or psychiatric disorders: A systematic review and meta-analysis","volume":"295","author":"Kim","year":"2021","journal-title":"J Affect Disord"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/yct.0000000000000754","article-title":"Electroconvulsive therapy use in psychiatric hospitalizations in Portugal: A nationwide descriptive study","volume":"37","author":"Mota","year":"2021","journal-title":"J ECT"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1642605","article-title":"Glymphatic system and psychiatric disorders: Need for a new paradigm","volume":"16","author":"Barlattani","year":"2025","journal-title":"Front Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852925100631","article-title":"Rebuilding the atrophied brain: 6-month nasal esketamine therapy expands key frontal and hippocampal regions and reduces serum neurofilament levels in patients with major depressive disorder. A proof-of-concept study of the Deptesk (Depression Treatment with Esketamine) study","volume":"30","author":"Rodr\u00edguez Lorente","year":"2025","journal-title":"CNS Spectr"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: Assessment of long-term safety in a phase 3, open-label study (Sustain-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011612.pub3","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder","volume":"9","author":"Dean","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.886918","article-title":"Glutamatergic system in depression and its role in neuromodulatory techniques optimization","volume":"13","author":"Khoodoruth","year":"2022","journal-title":"Front Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/hrp.0000000000000183","article-title":"Glutamatergic modulators in depression","volume":"26","author":"Henter","year":"2018","journal-title":"Harv Rev Psychiatry"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.05.037","article-title":"Optimally combining transcranial magnetic stimulation with antidepressants in major depressive disorder: a systematic review and meta-analysis","volume":"358","author":"Rakesh","year":"2024","journal-title":"J Affect Disord"},{"key":"B57","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jad.2024.04.093","article-title":"The complexity of treatment-resistant depression: a data-driven approach","volume":"358","author":"Rost","year":"2024","journal-title":"J Affect Disord"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1749006\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:36:03Z","timestamp":1786631763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1749006\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":57,"alternative-id":["10.3389\/fpsyt.2026.1749006"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1749006","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1749006"}}